LT3331877T - Pirazolpirimidino dariniai ir jų panaudojimas - Google Patents
Pirazolpirimidino dariniai ir jų panaudojimasInfo
- Publication number
- LT3331877T LT3331877T LTEPPCT/IL2016/050852T LT16050852T LT3331877T LT 3331877 T LT3331877 T LT 3331877T LT 16050852 T LT16050852 T LT 16050852T LT 3331877 T LT3331877 T LT 3331877T
- Authority
- LT
- Lithuania
- Prior art keywords
- pyrazolpyrimidine
- derivatives
- pyrazolpyrimidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200846P | 2015-08-04 | 2015-08-04 | |
| US201562268750P | 2015-12-17 | 2015-12-17 | |
| PCT/IL2016/050852 WO2017021969A1 (en) | 2015-08-04 | 2016-08-04 | Pyrazole pyrimidine derivative and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3331877T true LT3331877T (lt) | 2022-01-10 |
Family
ID=56738143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/IL2016/050852T LT3331877T (lt) | 2015-08-04 | 2016-08-04 | Pirazolpirimidino dariniai ir jų panaudojimas |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10376511B2 (OSRAM) |
| EP (1) | EP3331877B1 (OSRAM) |
| JP (1) | JP7083309B2 (OSRAM) |
| KR (1) | KR102698366B1 (OSRAM) |
| CN (1) | CN108137562B (OSRAM) |
| AU (2) | AU2016304464B2 (OSRAM) |
| CA (1) | CA2994644A1 (OSRAM) |
| CY (1) | CY1124898T1 (OSRAM) |
| DK (1) | DK3331877T3 (OSRAM) |
| ES (1) | ES2901349T3 (OSRAM) |
| HR (1) | HRP20211949T1 (OSRAM) |
| HU (1) | HUE057607T2 (OSRAM) |
| IL (1) | IL257282B (OSRAM) |
| LT (1) | LT3331877T (OSRAM) |
| MX (1) | MX384172B (OSRAM) |
| PL (1) | PL3331877T3 (OSRAM) |
| PT (1) | PT3331877T (OSRAM) |
| RS (1) | RS62728B1 (OSRAM) |
| RU (1) | RU2735522C2 (OSRAM) |
| SI (1) | SI3331877T1 (OSRAM) |
| SM (1) | SMT202100720T1 (OSRAM) |
| WO (1) | WO2017021969A1 (OSRAM) |
| ZA (1) | ZA201800671B (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2901349T3 (es) * | 2015-08-04 | 2022-03-22 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivado de pirazol pirimidina y usos del mismo |
| US11072599B2 (en) | 2017-02-01 | 2021-07-27 | Biotheryx, Inc. | Pyrazole compounds and uses thereof |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| AU2019219678A1 (en) * | 2018-02-08 | 2020-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020247345A1 (en) * | 2019-06-03 | 2020-12-10 | Biotheryx, Inc. | Non-hygroscopic crystalline salts of a pyrazole compound, and pharmaceutical compositions and use thereof |
| CN114127058B (zh) * | 2019-07-04 | 2024-06-25 | 深圳国顺康医药科技有限公司 | 一种杂环化合物、其药物组合物及用途 |
| TW202115024A (zh) | 2019-08-14 | 2021-04-16 | 美商英塞特公司 | 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物 |
| CN119930610A (zh) | 2019-10-11 | 2025-05-06 | 因赛特公司 | 作为cdk2抑制剂的双环胺 |
| EP4090159A4 (en) * | 2020-01-13 | 2024-01-24 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | PYRAZOLYLPYRIMIDINES AND THEIR USE |
| WO2021155050A1 (en) * | 2020-01-29 | 2021-08-05 | Biotheryx, Inc. | Kinase modulators, pharmaceutical compositions, and therapeutic applications |
| AU2021243726A1 (en) * | 2020-03-26 | 2022-09-29 | Janssen Pharmaceutica Nv | Aryl piperidines as monoacylglycerol lipase modulators |
| AU2022242818A1 (en) * | 2021-03-24 | 2023-10-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Pyrazolylpyrimidines for treating malignant solid tumor |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11752151B2 (en) * | 2021-07-12 | 2023-09-12 | Buddhist Tzu Chi Medical Foundation | Method for enhancing hair growth |
| US20230053307A1 (en) * | 2021-07-19 | 2023-02-16 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating skin disorders and conditions |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2025199440A1 (en) * | 2024-03-21 | 2025-09-25 | Edgewood Oncology | Methods of treating liposarcoma using a pyrazole compound |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE407132T1 (de) * | 2000-12-05 | 2008-09-15 | Vertex Pharma | Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen |
| EP1404669A2 (en) * | 2001-05-16 | 2004-04-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| GB0215844D0 (en) * | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| CN1976905A (zh) * | 2004-03-30 | 2007-06-06 | 大正制药株式会社 | 嘧啶衍生物以及与其应用有关的治疗方法 |
| JP2007145819A (ja) * | 2005-10-28 | 2007-06-14 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| WO2007138277A1 (en) * | 2006-05-26 | 2007-12-06 | Astrazeneca Ab | 2-carbocycloamino-4-imidaz0lylpyrimidines as agents for the inhbition of cell proliferation |
| WO2009071701A1 (en) * | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| RU2674017C2 (ru) | 2011-11-04 | 2018-12-04 | ДЖАСКО ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Аминопиримидиновые ингибиторы киназ |
| BR112016006319A2 (pt) | 2013-09-27 | 2017-08-01 | Nimbus Iris Inc | inibidores de irak e usos dos mesmos |
| JP6491202B2 (ja) * | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤 |
| ES2901349T3 (es) * | 2015-08-04 | 2022-03-22 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivado de pirazol pirimidina y usos del mismo |
| US11072599B2 (en) * | 2017-02-01 | 2021-07-27 | Biotheryx, Inc. | Pyrazole compounds and uses thereof |
| AU2019219678A1 (en) | 2018-02-08 | 2020-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
-
2016
- 2016-08-04 ES ES16753709T patent/ES2901349T3/es active Active
- 2016-08-04 RU RU2018107668A patent/RU2735522C2/ru active
- 2016-08-04 RS RS20211558A patent/RS62728B1/sr unknown
- 2016-08-04 SM SM20210720T patent/SMT202100720T1/it unknown
- 2016-08-04 KR KR1020187006128A patent/KR102698366B1/ko active Active
- 2016-08-04 PL PL16753709T patent/PL3331877T3/pl unknown
- 2016-08-04 CA CA2994644A patent/CA2994644A1/en active Pending
- 2016-08-04 PT PT167537091T patent/PT3331877T/pt unknown
- 2016-08-04 WO PCT/IL2016/050852 patent/WO2017021969A1/en not_active Ceased
- 2016-08-04 JP JP2018525826A patent/JP7083309B2/ja active Active
- 2016-08-04 AU AU2016304464A patent/AU2016304464B2/en active Active
- 2016-08-04 SI SI201631426T patent/SI3331877T1/sl unknown
- 2016-08-04 CN CN201680059148.XA patent/CN108137562B/zh active Active
- 2016-08-04 MX MX2018001395A patent/MX384172B/es unknown
- 2016-08-04 HR HRP20211949TT patent/HRP20211949T1/hr unknown
- 2016-08-04 US US15/748,536 patent/US10376511B2/en active Active
- 2016-08-04 LT LTEPPCT/IL2016/050852T patent/LT3331877T/lt unknown
- 2016-08-04 DK DK16753709.1T patent/DK3331877T3/da active
- 2016-08-04 HU HUE16753709A patent/HUE057607T2/hu unknown
- 2016-08-04 EP EP16753709.1A patent/EP3331877B1/en active Active
-
2018
- 2018-01-31 IL IL257282A patent/IL257282B/en active IP Right Grant
- 2018-01-31 ZA ZA2018/00671A patent/ZA201800671B/en unknown
-
2019
- 2019-08-12 US US16/538,550 patent/US10960003B2/en active Active
-
2021
- 2021-02-10 AU AU2021200839A patent/AU2021200839A1/en not_active Abandoned
- 2021-03-29 US US17/215,959 patent/US11925641B2/en active Active
- 2021-12-21 CY CY20211101124T patent/CY1124898T1/el unknown
-
2024
- 2024-02-05 US US18/432,931 patent/US20250049793A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20230014I1 (fi) | Foslevodopa ja foskarbidopa | |
| LT3331877T (lt) | Pirazolpirimidino dariniai ir jų panaudojimas | |
| LT3317284T (lt) | Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai | |
| LT3368534T (lt) | Valbenazino ditozilatas ir jo polimorfai | |
| LT3448386T (lt) | Izochinolin-3-ilo karboksamidai ir jų gamyba bei naudojimas | |
| EP3205103C0 (en) | INTER AND INTRA UNIFICATION BLOCK COPY | |
| LT3333191T (lt) | Anti-c10orf54 antikūnai ir jų panaudojimas | |
| LT3280441T (lt) | Anti-sortilino antikūnai ir jų naudojimo būdai | |
| LT3099717T (lt) | Antikūno molekulės tim-3-čiam ir jų panaudojimas | |
| LT3258951T (lt) | Anti-pvrig antikūnai ir jų panaudojimo būdai | |
| DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
| HUE055755T2 (hu) | Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk | |
| HRP20181742T1 (hr) | Hidroksialkil-supstituirani derivati feniltriazola i njihova uporaba | |
| LT3215532T (lt) | Anti-tim3 antikūnai ir jų naudojimo būdai | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| MA40933A (fr) | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines | |
| LT3394065T (lt) | Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai | |
| PL3157552T3 (pl) | Polipeptydy syntac i ich zastosowania | |
| LT3102555T (lt) | Junginių kompozicijos ir jų panaudojimas | |
| LT3319612T (lt) | Oksisteroliai ir jų naudojimo būdai | |
| LT3105253T (lt) | Antikūnai prieš jagged1 ir jų naudojimo būdai | |
| LT3204359T (lt) | Tetrahidroizochinolino dariniai | |
| DK3151875T3 (da) | Humane lever-scaffolds | |
| LT3177608T (lt) | Proteinkinazės c inhibitoriai ir jų naudojimo būdai | |
| DK3236991T3 (da) | Fgf21-derivater og anvendelser deraf |